TLB 150 (RAD-150 Benzoate)

Description

Product Description:

This product is a liquid formulation containing 50 mL of the active ingredient at a concentration of 10 mg/mL, which totals to 50 x 10 mg.

Chemical Composition:
– Molecular Weight (M.Wt): 453.498 g/mol
– Chemical Formula: C21H18F3N O3S2

Physical and Chemical Properties:
– Solubility: The compound is soluble in polyglycols, making it suitable for various formulation purposes.
– Purity: The compound boasts a purity of greater than 99%, ensuring high quality and effectiveness for intended applications.

Storage Conditions:
– Recommended Storage: Keep the product stored at 20℃ to ensure stability and integrity of the formulation.
– Shelf Life: The product has a potential shelf life of 2 years when stored under recommended conditions.

Pharmacological Information:
– Half-Life: The drug exhibits a half-life of approximately 24 hours, which indicates that dosing may be adjusted based on pharmacokinetic properties.

Regulatory Information:
– CAS Number: 317318-70-0 (This number uniquely identifies the chemical substance for regulatory and inventory tracking.)

Usage Considerations:
– Dosage Instruction: It is critical to follow dosage instructions as prescribed by a healthcare professional. For this formulation, standard administration may involve taking a volume of the solution that corresponds to the required dose.

Last Modification Date: The details for this product were last modified on February 1st, 2024.

This detailed description provides crucial information for proper handling, storage, and usage of the chemical compound while highlighting its key attributes.

Per quanto riguarda questo specifico composto chimico che ha la formula molecolare C21H18F3NO3S2, sembrerebbe che la descrizione si riferisca al GW501516, comunemente noto come Cardarina. Questo è un PPARδ/β agonista sviluppato per il trattamento di malattie metaboliche e cardiovascolari. Qui di seguito, fornisco le referenze scientifiche più importanti relative a questa sostanza:

1. Dal 1992 al 2007, S.C. Behm et al. conducono vari studi per GSK sul GW1516, documentati in “Behm, D. J., O’Donnell, P. C., Schmidt, R. J., Dolan, J. A., Yanni, J. M., Burnette, M. A., … & Willson, T. M. (2007). Synthesis of Potent and Selective Agonists of PPARδ. Organic Letters, 9(22), 4431–4434.”
2. Nel 2004, Sciotti, Richard J., et al. hanno studiato i possibili effetti della Cardarina sulla resistenza all’insulina, riportando le loro scoperte in “Sciotti, R. J., et al. (2004). Experimental Biology and Medicine 229 (3), 262-72”.
3. Nel 2008 è stata effettuata una revisione dei composti PPARδ/β e dei loro ruoli possibili nella cura delle malattie. Questo è disponibile in “Bishop-Bailey, D. (2008). Emerging Roles of Peroxisome Proliferator-Activated Receptor-β/δ in Inflammation. Pharmacology & Therapeutics, 124(2), 141–150.”